Chidamide in Combination With Decitabine in Non-Hodgkin's Lymphoma Relapsed After Chimeric Antigen Receptor
This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed after chimeric antigen receptor T cells infusion. The purpose is to evaluate the safety and efficacy of the treatment with chidamide in combination with decitabine.
Non Hodgkin Lymphoma
DRUG: Chidamide|DRUG: Decitabine|DRUG: Camrelizumab
CR rate, CR rate assess by investigators per the 2014 Lugano classification rate of subjects achieved complete response in all evaluable subjects, 2 years|Adverse events, Adverse events were defined according to the National Cancer Institute Common Terminology Criteria for Adverse Events (version 5.0), 2 years
This is a Phase I/II clinical trial for patients with r/r Non-Hodgkin's Lymphoma relapsed after chimeric antigen receptor T cells infusion. The purpose is to evaluate the safety and efficacy of the treatment with chidamide in combination with decitabine.